BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 20404007)

  • 1. Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer.
    Huang GS; Brouwer-Visser J; Ramirez MJ; Kim CH; Hebert TM; Lin J; Arias-Pulido H; Qualls CR; Prossnitz ER; Goldberg GL; Smith HO; Horwitz SB
    Clin Cancer Res; 2010 Jun; 16(11):2999-3010. PubMed ID: 20404007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer.
    Brouwer-Visser J; Lee J; McCullagh K; Cossio MJ; Wang Y; Huang GS
    PLoS One; 2014; 9(6):e100165. PubMed ID: 24932685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Reverse of the resistance to paclitaxel of the heparin binding-epidermal growth factor-like growth factor inhibitor in ovarian cancer].
    Tang XH; Lu MS; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2017 Feb; 52(2):110-115. PubMed ID: 28253574
    [No Abstract]   [Full Text] [Related]  

  • 4. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
    Tang X; Lu M; Li C; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer.
    Hamilton N; Austin D; Márquez-Garbán D; Sanchez R; Chau B; Foos K; Wu Y; Vadgama J; Pietras R
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29099049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer.
    Gotlieb WH; Bruchim I; Gu J; Shi Y; Camirand A; Blouin MJ; Zhao Y; Pollak MN
    Gynecol Oncol; 2006 Feb; 100(2):389-96. PubMed ID: 16300820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541.
    Hägerstrand D; Lindh MB; Peña C; Garcia-Echeverria C; Nistér M; Hofmann F; Ostman A
    Neuro Oncol; 2010 Sep; 12(9):967-75. PubMed ID: 20378689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silencing dishevelled-1 sensitizes paclitaxel-resistant human ovarian cancer cells via AKT/GSK-3β/β-catenin signalling.
    Zhang K; Song H; Yang P; Dai X; Li Y; Wang L; Du J; Pan K; Zhang T
    Cell Prolif; 2015 Apr; 48(2):249-58. PubMed ID: 25643607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor 2 axis supports the serum-independent growth of malignant rhabdoid tumor and is activated by microenvironment stress.
    Li T; Wang J; Liu P; Chi J; Yan H; Lei L; Li Z; Yang B; Wang X
    Oncotarget; 2017 Jul; 8(29):47269-47283. PubMed ID: 28521298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
    Tanno B; Mancini C; Vitali R; Mancuso M; McDowell HP; Dominici C; Raschellà G
    Clin Cancer Res; 2006 Nov; 12(22):6772-80. PubMed ID: 17121898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
    Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H
    Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
    Warshamana-Greene GS; Litz J; Buchdunger E; García-Echeverría C; Hofmann F; Krystal GW
    Clin Cancer Res; 2005 Feb; 11(4):1563-71. PubMed ID: 15746061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer.
    Ishibashi M; Nakayama K; Yeasmin S; Katagiri A; Iida K; Nakayama N; Fukumoto M; Miyazaki K
    Clin Cancer Res; 2008 May; 14(10):3149-55. PubMed ID: 18483383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line.
    Wang NN; Zhao LJ; Wu LN; He MF; Qu JW; Zhao YB; Zhao WZ; Li JS; Wang JH
    Asian Pac J Cancer Prev; 2013; 14(9):4983-8. PubMed ID: 24175763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Reversal effect of PI-3K/Akt pathway inhibitor LY294002 on multidrug resistance of ovarian cancer cell line A2780/Taxol].
    Shi XY; Cai XJ; Lei JX; Cao FJ; Pan DF; Chen P
    Ai Zheng; 2008 Apr; 27(4):343-7. PubMed ID: 18423117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Picropodophyllin inhibits proliferation and survival of diffuse large B-cell lymphoma cells.
    Strömberg T; Feng X; Delforoush M; Berglund M; Lin Y; Axelson M; Larsson O; Georgii-Hemming P; Lennartsson J; Enblad G
    Med Oncol; 2015 Jul; 32(7):188. PubMed ID: 26021470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TLR4/IL-6/IRF1 signaling regulates androgen receptor expression: A potential therapeutic target to overcome taxol resistance in ovarian cancer.
    Huang SL; Chang TC; Chao CCK; Sun NK
    Biochem Pharmacol; 2021 Apr; 186():114456. PubMed ID: 33556340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HOXB4 knockdown enhances the cytotoxic effect of paclitaxel and cisplatin by downregulating ABC transporters in ovarian cancer cells.
    Li Y; Sun J; Gao S; Hu H; Xie P
    Gene; 2018 Jul; 663():9-16. PubMed ID: 29660518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-98-5p/IGF2 Axis Influence Herceptin Sensitivity through IGF1R/HER2 Heterodimer Formation and AKT/mTOR Signal Pathway in HER2 Positive Breast Cancer.
    Zhang M; Li Z; Liu X
    Asian Pac J Cancer Prev; 2021 Nov; 22(11):3693-3703. PubMed ID: 34837929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.